Christina Bennett, MS

Christina Bennett, MS, is an independent medical journalist based in New Mexico. She is a member of the Association of Healthcare Journalists and the National Association of Science Writers and was one of a dozen journalists selected for the 2017 National Cancer Reporting Fellowships. She writes about a variety of medical topics, including oncology, healthcare policy, and cell and gene therapies.

All articles by Christina Bennett, MS

Emerging evidence suggests that a better understanding of T-cell behavior may help immune checkpoint inhibitors become more personalized.

Genitourinary Cancers Symposium

Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers

Christina Bennett, MS

February 25, 2021

Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.

Toni Choueiri, MD, discusses which drugs he believes are the most important in the future of renal c

Kidney Cancer

Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC

Christina Bennett, MS

February 22, 2021

Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

Prostate Cancer

Optimal Sequencing of ADT Identified for Localized Prostate Cancer

Christina Bennett, MS

December 17, 2020

Patients with prostate cancer who received androgen deprivation therapy in the adjuvant setting instead of the neoadjuvant setting had better clinical outcomes.

Ethical Issues in Medicine

Authors at Gynecologic Oncology Meeting Fail to Disclose Industry Relationships

Christina Bennett, MS

November 20, 2020

Most study authors at the 2019 Society of Gynecologic Oncology Annual Meeting failed to disclose industry relationships, a study found.

A recent article is only the latest in a series of studies drawing attention to the importance of di

Prostate Cancer

Screening of Prostate Cancer Patients for BRCA1/2 “Remains Unclear”

Christina Bennett, MS

December 3, 2019

Even though the EMBRACE study adds to the literature, according to authors the “best way” to screen men with germline DNA damage repair abnormalities “remains unclear.”

Next post in Prostate Cancer

Christina Bennett, MS

All articles by Christina Bennett, MS

Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers

Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC

Optimal Sequencing of ADT Identified for Localized Prostate Cancer

Authors at Gynecologic Oncology Meeting Fail to Disclose Industry Relationships

Screening of Prostate Cancer Patients for BRCA1/2 “Remains Unclear”

Dietary Patterns May Possibly Be Linked to Prostate Cancer Risk